Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.
Open Access
- 1 May 1990
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 171 (5) , 1527-1533
- https://doi.org/10.1084/jem.171.5.1527
Abstract
The majority of human NK cells express low affinity IgG Fc receptors (CD16+), whereas a minor subset of NK cells lack Fc receptor expression (CD16-). In contrast to CD16+ NK cells that express only p75 IL-2 receptors. CD16- NK cells constitutively co-express both p75 and p55 IL-2 receptors in vivo and preferentially respond to low concentrations of IL-2 with increased cytolytic activation and proliferation. Scatchard analysis demonstrated the presence of .apprx.1,2000 high affinity (.apprx.25 pM kD) and .apprx.9,600 intermediate affinity (.apprx.2 nM kD) IL-2 receptors on CD16- NK cells. CD16+ NK cells expressed only a single intermediate affinity IL-2 receptor of .apprx.1.9 nM kD (.apprx.9,000 sites per cell). The IL-2 binding data thus substantiated the phenotypic and functional studies and definitively show that the differential responsiveness of CD16- and CD16+ NK cells to IL-2 is manifested through different affinity IL-2 receptors.This publication has 17 references indexed in Scilit:
- Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cellsClinical Immunology and Immunopathology, 1990
- COMPARATIVE STUDIES OF HUMAN FCRIII-POSITIVE AND NEGATIVE NATURAL-KILLER CELLS1989
- Activation of natural killer cells via the p75 interleukin 2 receptor.The Journal of Experimental Medicine, 1989
- Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.The Journal of Immunology, 1989
- Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.Proceedings of the National Academy of Sciences, 1989
- In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.Journal of Clinical Oncology, 1987
- The interleukin 2 receptor. Functional consequences of its bimolecular structure.The Journal of Experimental Medicine, 1987
- The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.The Journal of Immunology, 1986
- Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.The Journal of Immunology, 1985
- Response of resting human peripheral blood natural killer cells to interleukin 2.The Journal of Experimental Medicine, 1984